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We have previously identified the engulfment and cell
motility 1 (ELMO1) as a susceptibility gene for diabetic
nephropathy. To elucidate the role of ELMO1 in the
pathogenesis of chronic renal injury, we examined the
expression of Elmo1 in the kidney of a rat model for chronic
glomerulonephritis (uninephrectomy plus anti-Thy1.1
antibody [E30] injection). We found that the expression of the
Elmo1 was significantly increased in the renal cortex and
glomeruli of uninephrectomized rats injected with E30
compared to controls. By in situ hybridization, the expression
of Elmo1 was shown to be elevated in the diseased kidney,
especially in glomerular epithelial cells. In COS cells, the
overexpression of ELMO1 resulted in a substantial increase
in fibronectin expression, whereas the depletion of the
ELMO1 by small interfering RNA (siRNA) targeting ELMO1
significantly suppressed the fibronectin expression in ELMO1
overexpressing and control cells. We also found that the
expression of integrin-linked kinase (ILK) was significantly
increased in ELMO1 overexpressing cells, and the
ELMO1-induced increase in fibronectin was partially, but
significantly, inhibited by siRNA targeting ILK. Furthermore,
we identified that the cell adhesion to ECMs was considerably
inhibited in cells overexpressing ELMO1. These results
suggest that the ELMO1 contributes to the development
and progression of chronic glomerular injury through the
dysregulation of ECM metabolism and the reduction in
cell adhesive properties to ECMs.
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In progressive renal diseases such as chronic glomerulo-
nephritis or diabetic nephropathy, its pathological lesion is
characterized by the accumulation of extracellular matrix
(ECM) proteins in the glomeruli.1–4 Recent studies have
indicated that the abnormal functions of glomerular cells, such
as glomerular epithelial cells (GEC) and glomerular mesangial
cells, may play a key role in the development and progression
of chronic glomerular injury.5–7 The detachment of GEC from
the glomerular basement membranes (GBMs),8,9 and/or
excess of the production of ECM proteins in glomerular
cells,10,11 is thought to mediate the establishment of the
chronic glomerular lesions. However, the precise mechanisms
that cause these abnormalities have not yet been elucidated.
We previously identified the engulfment and cell motility
1 gene (ELMO1) as a novel candidate for diabetic nephro-
pathy.12 We also demonstrated that the expression of ELMO1
could be observed mainly in the GEC, and was elevated in
cells cultured in high glucose conditions as well as in the
glomeruli of diabetic db/db mice. These results suggest that
ELMO1 may play a role in the development and progression
of chronic glomerular injury, such as diabetic glomerulo-
sclerosis. However, the contribution of the ELMO1 gene to
the pathogenesis of these glomerular diseases still remains
uncertain.
In the present study, we examined the role of the ELMO1
gene in the pathogenesis of chronic glomerular injury, and
provide evidence that the expression of the rat Elmo1 gene
was increased in the kidney of an animal model for chronic
glomerulonephritis. Furthermore, we suggest that ELMO1
may contribute to the development of the disease by increas-
ing the production of ECM proteins or by the reduction
in cell adhesive properties to the ECM.
RESULTS
Expression of the rat Elmo1 gene is increased in the kidney
of unilaterally nephrectomized rats injected with anti-Thy1.1
antibody [E30]
We first examined the expression of the Elmo1 gene in the
kidney of a rat model for chronic glomerulonephritis by
real-time quantitative polymerase chain reaction (PCR). As
shown in Figure 1a, the expression of the Elmo1 gene in the
renal cortex was significantly higher in uninephrectomized
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rats injected with E30 (monoclonal antibody for Thy-1.1)
than in control rats during the observation period. In isolated
glomeruli, Elmo1 expression was significantly increased at
seven and 10 weeks compared to control rats (Figure 1b). In
uninephrectomized rats injected with E30, the expression of
Elmo1 was gradually increased according to the progression
of the disease, and significantly increased at 10 weeks
compared to those at 2 weeks after injection with E30
(cortex: 8.772.1 and 3.570.8; glomeruli: 33.973.8 and
11.973.8, mean7s.d., 10 and 2 weeks, respectively,
Po0.0001), whereas those of control rats remained un-
changed during the observation period.
Results of in situ hybridization
By in situ hybridization, we also found that the expression of
Elmo1 was clearly elevated in the kidney of uninephrecto-
mized rats injected with anti-Thy-1.1 antibody [E30] (Figure
2e–g) compared to that of control rats (Figure 2a–c). The
elevation of Elmo1 expression was observed mainly in GEC
and in interstitial infiltrating cells (Figure 2j), especially in the
damaged glomeruli (Figure 2j and l) compared to relatively
unaffected glomeruli (Figure 2n). The expression of the
elmo1 could be detected also in the peritubular capillaries
(Figure 2j).
ELMO1 increases the expression of fibronectin
In order to ascertain the possible involvement of ELMO1 in
the development of chronic glomerular injury, we investi-
gated the effects of ELMO1 on the expression of fibronectin
by real-time quantitative reverse transcriptase (RT)-PCR and
enzyme-linked immunosorbent assay. As shown in Figure 3a
and b, the expression of fibronectin was markedly increased
in cells overexpressing ELMO1 compared to control cells. The
small interfering RNA (siRNA) treatment targeting ELMO1
resulted in significant silencing of ELMO1 expression in
LacZ-(control) and ELMO1-overexpressing cells (1575.4
and 3577.7% of those in cells treated with control siRNA for
LacZ- and ELMO1-overexpressing cells, respectively). The
treatment of siRNA for ELMO1 resulted in a significant
reduction of the expression of fibronectin in LacZ- and
ELMO1-overexpressing cells (fibronectin mRNA, Figure 3a:
6075.0% and 64712%; fibronectin protein excreted into
culture media, Figure 3b: 3273.6 and 6177.7% of those in
cells treated with control siRNA for LacZ- and ELMO1-
overexpressing cells, respectively).
ELMO1 overexpression inhibits cell adhesion to ECMs
To further understand the involvement of ELMO1 in the
development of chronic glomerular-injury, we examined the
effect of ELMO1 overexpression on the cell adhesion to the
extracellular matrices using COS cells stably overexpres-
sing ELMO1. As shown in Figure 4a–f, cell adhesion to
extracellular matrices was considerably inhibited in cells
overexpressing ELMO1 compared to control cells (collagen
type I: 0.2670.048 and 0.2070.045; collagen type IV:
0.4770.062 and 0.5870.041; fibronectin: 0.7170.011 and
0.3570.087; vitronectin: 0.1970.075 and 0.09470.014;
laminin: 0.7370.032 and 0.6770.033, of control cells for
ELMO1-line1 and ELMO1-line2, respectively).
The expression of ILK was increased in the ELMO1
overexpressing cells
We next examined the expression of integrin-linked kinase
(ILK), focal adhesion kinase (FAK) and Src, which were
considered to be involved in the regulation of cell adhesion or
ECM metabolism, in cells overexpressing ELMO1. As shown
in Figure 5a, the expression of ILK was significantly increased
in ELMO1 overexpressing cells compared with control
cells (1.7570.11- and 1.8270.077-fold increase compared
to control cells for ELMO1-line1 and ELMO1-line2, respec-
tively), whereas expression of FAK and Src did not differ
significantly between the ELMO1-overexpressing and
control cells.
The effects of ILK knockdown on the expression
of ECM genes
As shown in Figure 6, the treatment with ILK siRNA
could partially, but significantly, inhibit the increase in the
expression of collagen type I (a1) and fibronectin in cells
stably overexpressing ELMO1. The effects of ELMO1 over-
expression or knockdown of the ILK on the expression of ILK
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Figure 1 | The expression of Elmo1 in the kidney of a rat
model for chronic glomerulonephritis analyzed by real-time
quantitative RT-PCR. Total RNAs were prepared from (a) renal
cortex and (b) glomeruli 2, 3, 4, 5, 7, and 10 weeks after E30 or vehicle
injection. ’, Uninephrectomyþ E30 injection; &, uninephrectomy
and vehicle injection (control). Each bar indicates mean7s.d.,
*Po0.01 vs control.
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could be confirmed by Western blot analysis (Figure 6c) or by
ILK kinase assay (Figure 6d).
DISCUSSION
In this study, we demonstrated that the expression of rat
Elmo1 was increased in the kidney of an animal model for
chronic glomerular injury. Our data also suggest that the
overexpression of ELMO1 resulted in the accumulation of
ECM proteins and in the reduction in cell adhesion
properties to the ECM.
Although the precise mechanism of the development and
progression of chronic glomerulosclerosis remains uncertain,
cumulative evidence suggests that an abnormality of the func-
tion of glomerular cells, such as GECs or mesangial cells, plays
a pivotal role in the pathogenesis of chronic glomerular injury.
We have recently identified the ELMO1 gene as a novel
candidate for conferring susceptibility to diabetic nephro-
pathy, and we also demonstrated that the expression of Elmo1
was mainly observed in the GEC in the normal mouse
kidney.12 We show here, for the first time, that the expression
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Figure 2 | Results of in situ hybridization using the kidney of an uninephrectomized rat injected with E30. (a–h) In situ hybridization for
Elmo1, (a–d) uninephrectomy with vehicle (control), (e–h) uninephrectomyþ E30 injection, (a, e) 3 weeks, (b, f) 5 weeks, (c, d, g, h) 7 weeks after
vehicle or E30 injection. (a–c, e–g) Anti-sense, (d, h) sense probe. (i, k, m) Periodic acid Schiff stain and hematoxylin staining, (j, l, n) in situ
hybridization for Elmo1, glomerulus of nephrectomized rat 7 weeks after E30 injection. Bar¼ 100 mm.
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of the Elmo1 gene is significantly increased in the glomeruli
and cortex of uninephrectomized rats injected with E30 (an
animal model for chronic glomerular injury). The results of
in situ hybridization revealed that the elevation of Elmo1 gene
expression was mainly observed in the GEC, suggesting that
the increase in ELMO1 levels may contribute to the
development and progression of chronic glomerular injury.
To test this hypothesis, we examined the effects of siRNA
targeting ELMO1 on cells stably overexpressing ELMO1 and
LacZ (control). As we reported previously, the expression of
fibronectin was considerably increased in the cells over-
expressing ELMO1. In addition, the suppression of ELMO1
expression resulted in the significant reduction in the
expression of ECM gene, both in the cells overexpressing
ELMO1 and in control cells. From these observations, the
ELMO1 gene can be considered to be a potent regulator
for ECM gene expression, and the increase in the expression
of ELMO1 gene may contribute to the development and
progression of glomerulosclerosis via the excess accumulation
of ECM in the renal glomeruli.
Interestingly, we also identified that cells overexpressing
ELMO1 showed lower adhesive properties to the ECM
proteins compared to control cells. The GBM is considered to
function as a filtration barrier to maintain the homeostasis of
blood components, such as albumin. Since the GEC were
known to play a central role in maintaining the barrier
function of the GBM by tight adhesion to the GBM, the
detachment of the cells from the GBM may cause the loss of
the barrier function of the GBM, and consequently result in
the leakage of albumin into the urine.13–16 Therefore, it can
be speculated that the decrease in adhesive properties to the
ECM proteins by ELMO1 also contributes to the develop-
ment of proteinuria during chronic glomerular injury.
The precise mechanism for the ELMO1-induced reduction
in cell adhesive properties to the ECMs should be
investigated. It is well known that transmembrane receptors,
integrins, play a central role in the interaction between cells
and ECM proteins.17,18 Consequently, we examined the
expression of members of the integrin family in cells
overexpressing ELMO1, and identified a significant reduction
in a2 and b3 integrin mRNA in ELMO1 overexpressing cells
(data not shown). Therefore, we suggest that ELMO1
decreases the cell adhesion properties to the ECMs through,
at least in part, the reduction in the expression of these
integrins.
In order to elucidate the mechanism of the ELMO1-
induced increase in ECM expression and reduction in cell
adhesive properties further, we investigated the effects of
ELMO1 on the expression of several protein kinases, such as
FAK, ILK, and Src, which have all been reported to contribute
to the regulation of ECM protein metabolism and/or cell
adhesion properties.19–23 We found that the expression of ILK
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Figure 3 | The expression of fibronectin in the cells stably
transfected with LacZ or ELMO1. (a) Fibronectin mRNA determined
with real-time quantitative RT-PCR (b) excretion of fibronectin protein
into culture media measured by enzyme-linked immunosorbent
assay. (c) Western blot analysis using anti-FLAG monoclonal antibody.
LacZ: LacZ overexpressing cells, ELMO1: ELMO1 overexpressing cells,
Control: cells treated with control oligonucleotide, ELMO1 siRNA: cells
treated with siRNA targeting ELMO1. Each bar indicates mean7s.d. of
three independent experiments. *Po0.05, **Po0.01.vs cells treated
with control siRNA.
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Figure 4 | ELMO1 overexpression inhibits cell-adhesion to ECMs.
The ability of LacZ and ELMO1 overexpressing cells to adhere to ECMs
was examined as described in the Materials and Methods section.
(a) Collagen type I, (b) collagen type IV, (c) fibronectin, (d) vitronectin,
(e) laminin, (f) no ECM. Results are presented as mean7s.d. from four
or five independent experiments. **Po0.01 vs LacZ. (g) Western
blot analysis using anti-FLAG monoclonal antibody.
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increased significantly in ELMO1 overexpressing cells,
whereas the expression of FAK and Src did not differ
between ELMO1 overexpressing and control cells. Since ILK
is known to be responsible for the regulation of cell adhesion,
and for the accumulation of ECM proteins by several types of
cytokines, such as TGF-b, the increase in ILK was considered
to mediate the effects of ELMO1 in the expression of ECMs
and the changes in the cell adhesion properties. Moreover, in
further support of this hypothesis, the results of siRNA
experiments targeting ILK indicated that the suppression of
ILK mRNA partially, but significantly, abolished the ELMO1-
induced increase in the expression of type 1 collagen (a1) and
fibronectin (Figure 6).
The molecular mechanism of the influence of ELMO1 on
the expression of the genes reported here and/or cell adhesion
properties is still unknown. Previous reports suggested that
ELMO1 cooperates with Dock180 to function as an activator
for Rac-1.24,25 Accordingly, we next examined the effects of
Rac-1 and coexpression of Dock180 with ELMO1 on the
expression of ECM genes. However, no significant additional
effects of these factors on the expression of these genes were
detected (data not shown), suggesting the effects of ELMO1
on the regulation of expression of these genes and/or cell
adhesion properties were independent of Rac-1. The
elucidation of the precise mechanisms requires further study.
In conclusion, we have shown that the expression of
Elmo1 was increased in the kidney of an animal model for
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Figure 6 | The effects of ILK knockdown on the ELMO1-induced increase in ECM gene expression. (a) Collagen type 1 (a1), (b) fibronectin.
Control: cells treated with control siRNA. ILK siRNA: cells treated with siRNA targeting ILK. Results were expressed as means7s.d. of three
independent experiments. **Po0.01 vs cells treated with control siRNA. (c) Western blot analysis for ILK. (d) Result of ILK activity assay.
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chronic glomerular injury. The examination of cells over-
expressing ELMO1 also indicated that the increase in ELMO1
expression causes the increase in expression of ECMs and the
reduction in cell adhesive properties. These results suggest
that ELMO1 plays a pivotal role in the development and
progression of chronic glomerular injury, and may be a new
target for the treatment of chronic glomerular disease.
MATERIALS AND METHODS
Materials
COS-7 cells were obtained from the Japan Health Sciences
Foundation (Osaka, Japan), Dulbecco’s modified Eagle medium,
phosphate-buffered saline (PBS), penicillin G, streptomycin, and
Trypsin-ethylenediaminetetraacetic acid (EDTA) were purchased
from Invitrogen (Carlsbad, CA, USA). SYBR Green I and Crystal
violet were obtained from CAMBREX Bio Science (Rockland, ME,
USA) and Wako Pure Chemical Industries (Osaka, Japan),
respectively. Ex Taq Buffer, dNTPs, and Ex Taq DNA polymerase
were purchased from TaKaRa Bio (Otsu, Shiga, Japan).
Induction of E30 (monoclonal antibody against Thy-1.1
antigen)-induced chronic nephritis model in unilaterally
nephrectomized rats
Seven-week-old male Wistar rats (Japan SLC, Inc., Shizuoka) were
subjected to ligation of the left renal artery and renal vein, and then
the left kidney was removed under sodium pentobarbital anesthesia.
One week after the unilateral nephrectomy, the animals were divided
into two groups that received either E30 (70 mg in 400 ml of saline) or
saline vehicle via the tail vein.26
Isolation of total RNA from renal cortex and glomerulus
On the indicated days after injection of E30 or saline vehicle,
animals were anesthetized with sodium pentobarbital, and the
kidneys were perfused with PBS through the abdominal aorta. Next,
the kidneys were removed, and the renal cortex was extracted and
the isolated glomeruli were prepared by standard sieving techniques.
Total RNA was extracted from the renal cortex and glomeruli by a
standard technique followed by ethanol precipitation. Briefly, a
small piece of the renal cortex or isolated glomeruli was
homogenized in 500 ml of ISOGEN (Nippon Gene, Tokyo, Japan).
After addition of 400 ml chloroform, the mixture was centrifuged for
15 min at 41C (10 000 r.p.m.). The supernatant was mixed with an
equal volume of isopropylalcohol and centrifuged for 10 min at 41C
(10 000 r.p.m.). The supernatant was precipitated with 70% ethanol
three times and dried under reduced pressure.
In situ hybridization
For tissue preparation, the kidneys were perfused through the
abdominal aorta with 4% paraformaldehyde in PBS under
pentobarbital anesthesia. The renal tissue was immediately dissected
and immersed in a fresh portion of the same fixative at 41C
overnight. Fixed samples were thoroughly rinsed with PBS,
dehydrated by passage through an alcohol series, and cleared in
xylene. In situ hybridization was performed on paraffin-embedded
sections. Probes for in situ hybridization studies were prepared
from cDNA fragments encoding Elmo1 as previously described.12
The tissue sections were permeabilized with proteinase K (Roche
Diagnostics, Basel, Switzerland), and acetylated with 0.1 mol/l
triethanolamine containing 0.25% acetic anhydride. Next, the
sections were hybridized with 500 ng/ml digoxigenin (DIG)-labeled
cRNA probe for 17 h at 501C in a hybridization buffer (50%
deionized formamide, 1 Denhardt’s solution, 10% dextran
sulfate, 600 mmol/l NaCl, 0.025% sodium dodecyl sulfate, 5 mmol/
l EDTA pH 8.0, 0.25 mg/ml yeast tRNA, and 10 mmol/l Tris-HCl pH
7.6). After hybridization, the samples were rinsed with 5 sodium
chloride–sodium citrate, then stringently rinsed with 2 sodium
chloride–sodium citrate containing 50% formamide, and finally
rinsed thoroughly with 0.2 sodium chloride–sodium citrate. The
samples were then immersed in 1.5% blocking reagent dissolved in
DIG buffer 1 (100 mmol/l Tris-HCl, pH 7.5, containing 150 mmol/l
NaCl) for 60 min at room temperature. After preincubation in
normal rabbit serum at a dilution of 1:500 in DIG buffer 1 for
30 min, the samples were incubated in anti-DIG sheep polyclonal
antibodies in DIG buffer 1 for 30 min at room temperature and then
rinsed with DIG buffer 1. These samples were incubated in
biotinylated anti-sheep rabbit polyclonal antibodies in DIG buffer
1 for 30 min at room temperature and rinsed again with DIG buffer
1. Next, the samples were treated with avidin-biotinylated horse-
radish peroxidase complex solution (Vector Laboratories, Burlin-
game, CA, USA) at room temperature for 60 min, followed by
extensive washing with DIG buffer 1. After treatment with 0.1%
3,30-diaminobenzidine hydrochloride substrate dissolved in
50 mmol/l Tris-HCl (pH 7.4) containing 0.05% H2O2 for 5 min at
room temperature in the dark, the sections were examined for
expression of the specific gene of interest. The reaction was stopped
by rinsing in Tris-EDTA buffer (10 mmol/l Tris-HCl, pH 7.6,
containing 1 mmol/l EDTA), and the target mRNA signals were
visualized. The sections were counterstained with periodic acid-
Schiff reagent, dehydrated, and finally mounted in Entellan New
(Merck, Whitehouse Station, NJ, USA).
Preparation of cells stably overexpressing ELMO1
A full-length cDNA for human ELMO1 was amplified from a human
spleen cDNA library using appropriate sense (50-ACGCTGTAG
GATCCTCATTC-30) and anti-sense (50-TTTCAGTTACAGTCATA
GACGAAGT-30) primers. The amplified product was purified and
subcloned into the pcDNA3.1 vector (Invitrogen, Carlsbad, CA,
USA) at its multiple cloning site. The expression vectors for
hELMO1 and LacZ (control) were introduced into COS-7 cells using
the liposome transfection procedure (FuGene 6, Roche Diagnostics,
Basel, Switzerland), and the cells were selected in the media
containing neomycin analog, G418 (Invitrogen, Carlsbad, CA,
USA). The cloned cell lines were maintained in Dulbecco’s modified
Eagle medium containing 10% fetal bovine serum (Gemini Bio-Pro-
ducts, Woodland, CA, USA), penicillin G (50 U/ml), and strepto-
mycin (50 mg/ml).
siRNA experiments
A 21-nucleotide synthetic siRNA duplex was prepared by FASMAC
(Atsugi, Kanagawa, Japan). The siRNA sequences used for targeting
ELMO1 or ILK were as follows. For ELMO1: 50-GTG CTC ACC TTT
AAC CTC CTT-30, which corresponds to nucleotide positions
1147–1165 in ELMO1 cDNA (Genbank Accession NM_014800). For
ILK: 50-CCC GGC TCA GGA TTT TCT CTT-30, which corres-
ponds to nucleotide positions 875–893 in ILK cDNA (Genbank
Accession NM_004517). As a control, an siRNA with a non-silencing
oligonucleotide sequence (QIAGEN, Hilden, Germany) was used.
COS-7 cells were transfected with the siRNA using LipofectamineTM
2000 (Invitrogen, Carlsbad, CA, USA). Forty-eight hours after
siRNA transfection, total RNA was extracted for real-time
quantitative RT-PCR.
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Real-time quantitative RT-PCR
Total RNA was extracted from COS-7 cells using Rneasys Mini
columns (QIAGEN, Hilden, Germany), and first-strand cDNA was
prepared with the SuperScriptTM III First-Strand Synthesis System
(Invitrogen, Carlsbad, CA). Real-time quantitative RT-PCR was
carried out in an ABI PRISMs 7000 Sequence Detection System
(Applied Biosystems Japan, Tokyo, Japan) using SYBR Green I. The
amplifications were performed in 25 ml reaction volumes containing
Ex Taq Buffer, 200 nM dNTPs, 1/20 000 diluted SYBR Green I,
800 nM of each primer, 0.05 U Ex Taq DNA polymerase, and 2.75 ng
TaqStart Antibody (BD Biosciences, San Jose, CA, USA). The
thermal profile used was 501C for 2 min, 951C for 10 min, followed
by 40 cycles of 951C for 30 s, 631C for 30 s, and 721C for 30 s. The
data were normalized by glyceraldehyde-3-phosphate dehydrogenase
to account for differences in reverse transcriptional efficiencies. The
gene-specific primers we used in this study are described in Table 1.
Enzyme-linked immunosorbent assay for fibronectin
A QuantiMatrixTM enzyme-linked immunosorbent assay strips
(Chemicon, Temecula, CA, USA) was used for the measurement
of fibronectin secreted to the conditioned media collected for 24 h.
Samples were incubated with rabbit anti-fibronectin antibody for
1 h at room temperature in the strips. After the plate was washed
four times with wash buffer, goat anti-rabbit IgG conjugated with
horseradish peroxidase was added and incubated for 30 min, and the
strips were reacted with TMB/E substrate for 10 min. The concen-
trations of fibronectin were determined to measure the absorbance
at 450 nm. DNA concentrations were determined using CyQUANT
Cell Proliferation Assay Kit (Molecular Probes, Eugene, OR, USA).
Western blot analysis
Cells were lysed with cell lysis buffer (50 mM N-2-hydroxyethyl-
piperazine-N0-2-ethanesulfonic acid, 150 mM NaCl, 10% glycerol,
1.5 mM MgCl2, 1 mM ethyleneglycol-bis-aminoether-N,N
0-tetra-
acetic acid, 1% Triton X-100, 0.1% sodium dodecyl sulfate), and
the extracted proteins were analyzed on 12.5% sodium dodecyl
sulfate-polyacrylamide gels. The proteins were transferred to
Immobilion membrane (Millipore, Bedford, MA, USA). The
membrane was blocked using 1% skim milk (Becton Dickinson,
MD,, USA) in PBS, and reacted with the anti-FLAG monoclonal
antibody (Sigma-Aldrich, St Louis, USA) or anti-ILK polyclonal
antibody (Upstate, Lake Placid, NY, USA), followed by incubating
with horseradish peroxidase conjugated second antibody. Immuno-
reactive bands were detected in ECL plus Western Blotting Detection
System (Amersham Biosciences, UK).
ILK activity assay
Cells were solubilized with lysis buffer 2 (20 mM Tris (pH 7.5),
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM
sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na3VO4,
1 mg/ml Leupeptin). The cell lysate was centrifuged at 10 000 g for
15 min at 41C. Two hundred and fifty micrograms of extracted
protein was immunoprecipitated overnight with 1 mg of rabbit anti-
ILK polyclonal antibody (Upstate), and then 30 ml of protein A
agarose beads were added followed by 3 h rotation at 41C. The beads
were washed twice with lysis buffer 2 and kinase buffer (25 mM Tris
(pH7.5), 5 mM b-glycerophosphate, 2 mM dithiothreitol, 0.1 mM
Na3VO4, 10 mM MgCl2), and were suspended in kinase buffer
containing 200mM ATP and 1 mg of glycogen synthase kinase-3
fusion protein. Phospholylated-glycogen synthase kinase-3 was
detected by Western blot analysis using rabbit anti-phospho-
glycogen synthase kinase-3a/b (Ser21/9) polyclonal antibody (Cell
Signaling Technology, Beverly, MA, USA).
Cell-adhesion assays
The cell-adhesion assays were performed in CytoMatrix Cell
Adhesion Strips (Chemicon). Cells were detached with Trypsin-
EDTA, resuspended in non-enzymatic Dulbecco’s modified Eagle
medium containing 10% fetal bovine serum and plated on each well
(5 105 cells per well). After incubation at 371C for 60 min in a CO2
incubator, the plates were washed with PBS containing Ca2þ and
Mg2þ to remove the non-adherent cells. The adherent cells were
fixed and stained with 0.2% crystal violet in 10% ethanol solution
for 5 min. After washing twice with PBS, the cell-bound stain was
extracted by incubating the cells in a solubilization buffer (0.05 M
NaH2PO4, pH 4.5 in 50% ethanol), and the absorbance was
measured at 540 nm.
Statistical analysis
For statistical testing, comparisons among three or more groups
were analyzed by one-way analysis of variance, followed by Scheffe’s
tests to evaluate statistical differences between the experimental and
control groups. Po0.05 was considered to be significant.
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